As of 9:30 AM on the 2nd, Celltrion is trading at 344,500 KRW, up 0.15% from the previous day. The trading volume is 261,665 shares, which is 21.33% of the previous day's volume. Celltrion is known as a protein and biopharmaceutical manufacturing company.
On November 27, Hyungsoo Kim, a researcher at Cape Investment & Securities, stated, "A company that started the biosimilar business domestically and is leading the global biosimilar market. It is sequentially launching biopharmaceuticals with expired patents and is also developing and launching biobetters that can be sold at higher prices with higher profits than existing products. It is developing a COVID-19 antibody treatment, which could be launched in the first half of 2021. The company is growing while realizing high profits." He set Celltrion's target price at 390,000 KRW.
Over the past five days, individual investors have net purchased 75,341 shares of Celltrion, while foreigners and institutions have net sold 60,369 shares and 24,029 shares, respectively.
※ Source: AI Investment Assistant AI Rassiro
※ This article was generated in real-time by an article auto-generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
